|
Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC) Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC) Clinical research trials and Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC) healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC). Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC) Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC) clinical trial. Human subjects often receive the most effective healthcare possible for their Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC) condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC)  Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC)
Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC)
For Condition: Carcinoma, Non-Small-Cell Lung,Lung Neoplasms
Status: Completed
Sponsor(s): Pfizer ,
Synopsis: The primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for Non small-cell lung cancer (NSCLC)
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: Eligible patients must be at least 18 years of age with a diagnosis of NSCLC that has gotten worse during or after treatment with platinum-based chemotherapy. Patients must have at least one tumor that can be evaluated by the doctor during the investigational drug treatment. Any side-effects from prior chemotherapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function. Exclusion Criteria: Any of the following will exclude patients from study participation: receipt of more than 1 prior regimen of chemotherapy for NSCLC (repeat of the same chemotherapy at different points in time count as 1 regimen). Irradiation to 25% or more of bone marrow, prior high dose chemotherapy with bone marrow or stem cell support, current participation in other clinical trials, pregnant or breast-feeding women, known HIV-positive or AIDS-related illness.
Total Enrollment:
Location and Contact Information:
Research Center
Rancho Mirage, California, 92270
United States
Research Center
West Boylston, Massachusetts, 01583
United States
Research Center
Lebanon, New Hampshire, 03756
United States
Research Center
Chicago, Illinois, 60637-1463
United States
Research Center
Louisville, Kentucky, 40202
United States
Research Center
Arlington, Texas, 76012
United States
Research Center
Los Angeles, California, 90048
United States
Research Center
Nashville, Tennessee, 37232-6868
United States
Research Center
Greenbrae, California, 94904-2007
United States
Research Center
Dallas, Texas, 75390
United States
Research Center
Berkeley, California, 94704
United States
Research Center
Ann Arbor, Michigan, 48109
United States
Additional Information:
Study ID Numbers: 196-ONC-0100-005;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034957
Other Lung Neoplasms Studies:
1. Utility of Anatometabolic Imaging for Radiation Treatment Planning for Lung Cancer
2. Safety/Efficacy study of immunoconjugate with docetaxel in non-small cell lung carcinoma
3. A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin versus Gemcitabine and Cisplatin in Patients with Advanced, Previously Untreated Non-Small Cell Lung Cancer
4. Iressa Expanded Access Program (EAP)
5. A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
Related Studies:
Other Lung Neoplasms Clinical Trials
Other Michigan Clinical Trials
Other Ann Arbor Clinical Trials
Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC)
|
|
|
|
|
|
|
|
